XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.
A
A

Abbott


Yangiliklar

WHO approves first mpox diagnostic test for emergency use

UPDATE 4-WHO approves first mpox diagnostic test for emergency use Updates Oct. 3 story to add company statement in paragraph 4 Oct 3 (Reuters) - The World Health Organization authorized Abbott Laboratories' ABT.N mpox diagnostic test for emergency use on Thursday, the first such approval in the agency's effort to bolster testing capabilities in countries facing outbreaks of the disease.
A
R
L

Jury urged to hold formula makers responsible for premature baby's illness

UPDATE 1-Jury urged to hold formula makers responsible for premature baby's illness Adds material from Abbott, Mead Johnson opening statements By Brendan Pierson Oct 2 (Reuters) - A lawyer for a Missouri mother on Wednesday urged jurors to hold Abbott ABT.N , Reckitt's RKT.L Mead Johnson unit and St. Louis Children's Hospital responsible for a severe intestinal illness that she says her prematurely born son developed after the hospital fed him the companies' formulas.
A

Jury urged to hold formula makers responsible for premature baby's illness

Jury urged to hold formula makers responsible for premature baby's illness By Brendan Pierson Oct 2 (Reuters) - A lawyer for a Missouri mother on Wednesday urged jurors to hold Abbott ABT.N , Reckitt's RKT.L Mead Johnson unit and St. Louis Children's Hospital responsible for a severe intestinal illness that she says her prematurely born son developed after the hospital fed him the companies' formulas.
A

U.S. STOCKS Dine Brands, Pinterest, Nike

BUZZ-U.S. STOCKS ON THE MOVE-Dine Brands, Pinterest, Nike Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes took a beating on Tuesday as reports of escalating tensions in the Middle East made investors sell riskier assets, with the benchmark S&P 500 hitting its lowest in over a week.
A
A
C
L
N
P
S
L
U
U
L
A
C
J
M

Uptake of Dexcom's OTC glucose monitor Stelo outpaces Abbott's Lingo, Citi says

BUZZ-Uptake of Dexcom's OTC glucose monitor Stelo outpaces Abbott's Lingo, Citi says ** Brokerage Citi says early uptake of Dexcom's DXCM.O over-the-counter continuous glucose monitor Stelo is ahead of Abbott's ABT.N Lingo ** Stelo is gaining traction benefitting from an earlier launch compared to Lingo - Citi ** Adds app data points to a recovery for Dexcom, after the glucose monitor maker slashed its annual revenue forecast ** Brokerage says downloads of apps for Dexcom's continuous glucose mo
A

UK's Reckitt falls after court trial over premature baby formula begins

BUZZ-UK's Reckitt falls after court trial over premature baby formula begins ** Shares of Enfamil formula maker Reckitt RKT.L down 1.15% at 4,524p ** Co's unit Mead Johnson, along with US-based Abbott ABT.N , is facing a trial over its premature baby formula causing a severe intestinal illness ** Plaintiffs argue companies failed to warn about the
A

UK Stocks-Factors to watch on Oct 1

UPDATE 1-UK Stocks-Factors to watch on Oct 1 Adds new items, updates futures Oct 1 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher, with futures FFIc1 up 0 .4%. * HALEON: Pfizer PFE.N offloaded shares worth roughly $3.26 billion in Haleon HLN.L at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said.
A
G
P
R

UK Stocks-Factors to watch on Oct 1

UK Stocks-Factors to watch on Oct 1 Oct 1 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher, with futures FFIc1 up 0.34% * HALEON: Pfizer's PFE.N stake sale in British consumer healthcare company Haleon HLN.L has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
A
P

Abbott, Reckitt face trial over premature baby formula amid alarm from doctors

CORRECTED-Abbott, Reckitt face trial over premature baby formula amid alarm from doctors Corrects title of Jonathan Davis in paragraph 9, to Chief of Newborn Medicine at Tufts Medical Center Doctors fear losing access to essential formulas for premature babies Plaintiffs argue companies failed to warn about NEC risk from cow's milk-based formula By Brendan Pierson Sept 30 (Reuters) - A Missouri mother and her lawyers this week will aim to convince a jury that Abbott ABT.N , Reckitt's RKT.L Mead
A

Indian shares set to open higher on US rate-cut euphoria

INDIA STOCKS-Indian shares set to open higher on US rate-cut euphoria BENGALURU, Sept 20 (Reuters) - Indian shares are set to open higher on Friday, as an outsized interest rate reduction by the U.S. Federal Reserve and the anticipation of a soft landing for the world's largest economy boosted risk appetite across global markets. The GIFT Nifty GIFc1 was at 25,523 points, as of 07:55 a.m.
A
U

U.S. STOCKS Children's Place, US energy sector, retailers

BUZZ-U.S. STOCKS ON THE MOVE-Children's Place, US energy sector, retailers Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes soared on Thursday with the S&P 500 and the Dow hitting intraday record highs after the Federal Reserve kicked off its monetary easing cycle with half-a-percentage point reduction and forecast more interest rate cuts were on the hor
A
A
C
C
I
J
L
M
N
T
A
U
F
R
U
U
S
D

Abbott Declares Qtrly Common Dividend Of 55 Cents/Shr

BRIEF-Abbott Declares Qtrly Common Dividend Of 55 Cents/Shr Sept 19 (Reuters) - Abbott Laboratories ABT.N : ABBOTT - DECLARED A QUARTERLY COMMON DIVIDEND OF 55 CENTS PER SHARE ABBOTT DECLARES 403RD CONSECUTIVE QUARTERLY DIVIDEND Source text for Eikon: ID:nPnbB2dYca Further company coverage: ABT.N
A

Piper Sandler initiates coverage on Abbott with 'overweight' rating

BUZZ-Piper Sandler initiates coverage on Abbott with 'overweight' rating ** Brokerage Piper Sandler initiates coverage on Abbott Laboratories ABT.N with overweight rating and PT of $131 ** Says while execution has been strong, ABT shares have underperformed YTD due to the ongoing litigation related to necrotizing enterocolitis (NEC) in premature babies, which has been an overhang ** Brokerage believes the potential damages related to the lawsuit are already priced in ** Considers ABT to be "one
A

U.S. Athira Pharma, Lowe's Companies, P&G

U.S. RESEARCH ROUNDUP-Athira Pharma, Lowe's Companies, P&G Sept 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Athira Pharma, Lowe's Companies and P&G on Thursday. HIGHLIGHTS * Athira Pharma Inc ATHA.O : Mizuho cuts to neutral from outperform * Five Below Inc FIVE.O : JP Morgan cuts to underweight from neutral * Lowe's Companies Inc LOW.N : TD Cowen raises target price to $265 from $240 * P&G PG.N : JP Morgan rai
A
A
C
D
M
N
T
A
C

India's pharma index climbs after bumper Fed rate cut

BUZZ-India's pharma index climbs after bumper Fed rate cut ** India's Nifty pharma index .NIPHARM climbs 0.5%, snapping three straight sessions of losses ** Rise after the U.S. Federal Reserve started its monetary easing cycle with a large 50-basis-point rate cut MKTS/GLOB ** Indian pharma firms have a sizeable exposure to U.S. markets and earn a significant share of their rev from the geography ** Eighteen of the 21 index constituents are trading in green; top gainers Abbott India ABOT.NS and A
A

Indian shares set to open higher

INDIA STOCKS-Indian shares set to open higher BENGALURU, Sept 10 (Reuters) - Indian shares are set to open higher on Tuesday, tracking a rebound in global stocks ahead of the key U.S. inflation data and the Federal Reserve's interest rate decision. The GIFT Nifty GIFc1 was at 25,035 points, as of 08:06 a.m. IST, indicating the NSE Nifty 50 .NSEI will open above its previous close of 24,936.4. The benchmark Nifty 50 rose for the first time in four sessions on Monday, led by gains in consumer stoc
A
A

FDA Says Abbott Diabetes Care Inc Issues Recall For Certain Freestyle Libre 3 Sensors Due To Risk For Inaccurate High Glucose Readings

BRIEF-FDA Says Abbott Diabetes Care Inc Issues Recall For Certain Freestyle Libre 3 Sensors Due To Risk For Inaccurate High Glucose Readings Sept 5 (Reuters) - FDA: FDA: ABBOTT DIABETES CARE INC ISSUES RECALL FOR CERTAIN FREESTYLE LIBRE 3 SENSORS DUE TO RISK FOR INACCURATE HIGH GLUCOSE READINGS Further company coverage: ABT.N
A

Abbott U.S. Availability Of Lingo, Co's First Continuous Glucose Monitoring System Available Without Prescription

BRIEF-Abbott U.S. Availability Of Lingo, Co's First Continuous Glucose Monitoring System Available Without Prescription Abbott Laboratories ABT.N : ABBOTT: U.S. AVAILABILITY OF LINGO, CO'S FIRST CONTINUOUS GLUCOSE MONITORING SYSTEM AVAILABLE WITHOUT PRESCRIPTION ABBOTT: LINGO IS AVAILABLE IN THREE OPTIONS FOR $49, $89, AND $249 Source text for Eiko
A

Abbott follows rival Dexcom with OTC glucose monitor launch in US

UPDATE 3-Abbott follows rival Dexcom with OTC glucose monitor launch in US Adds details on the device in paragraph 3, background in paragraphs 6-7 By Sneha S K Sept 5 (Reuters) - Abbott ABT.N has launched its over-the-counter continuous glucose monitoring system in the U.S., the company said on Thursday, making it the second such device on the market to help people track their blood sugar levels.
A

Abbott launches over-the-counter continuous glucose monitor in the US

Abbott launches over-the-counter continuous glucose monitor in the US Sept 5 (Reuters) - Abbott ABT.N has launched its over-the-counter continuous glucose monitoring system Lingo in the United States, the company said on Thursday. Reporting by Sneha S K; Editing by Janane Venkatraman
A



Shartlar

Ommabop aktivlar

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.